Deep Medicine Acquisition Corp. (NASDAQ:DMAQ – Get Rating) was the target of a significant increase in short interest in the month of September. As of September 15th, there was short interest totalling 2,600 shares, an increase of 8.3% from the August 31st total of 2,400 shares. Approximately 0.0% of the shares of the company are sold short. Based on an average daily volume of 22,500 shares, the short-interest ratio is presently 0.1 days.
Deep Medicine Acquisition Price Performance
Shares of DMAQ opened at $10.08 on Wednesday. Deep Medicine Acquisition has a 1 year low of $9.70 and a 1 year high of $10.99. The company's fifty day moving average is $10.05 and its two-hundred day moving average is $10.01.
Get Deep Medicine Acquisition alerts:Institutional Trading of Deep Medicine Acquisition
Hedge funds and other institutional investors have recently made changes to their positions in the company. Karpus Management Inc. acquired a new stake in Deep Medicine Acquisition in the fourth quarter valued at about $19,801,000. Saba Capital Management L.P. acquired a new stake in shares of Deep Medicine Acquisition in the 4th quarter valued at approximately $8,908,000. Beryl Capital Management LLC purchased a new stake in shares of Deep Medicine Acquisition in the fourth quarter valued at approximately $6,012,000. Oaktree Capital Management LP acquired a new position in Deep Medicine Acquisition during the fourth quarter worth $4,173,000. Finally, Hsbc Holdings PLC purchased a new position in Deep Medicine Acquisition in the first quarter worth $2,976,000. Hedge funds and other institutional investors own 89.62% of the company's stock.
About Deep Medicine Acquisition
(Get Rating)Deep Medicine Acquisition Corp. does not have significant operations. The company intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It focuses on identifying businesses in the healthcare industry.
See Also
- Get a free copy of the StockNews.com research report on Deep Medicine Acquisition (DMAQ)
- Don't Give Up on These Q3 Losers
- The Anatomy of a Great Pension Plan
- 3 Safe Earnings Plays for a Risk-Off Market
- Tyson Foods Takes a Lickin' and Keeps on Tickin' Lower
- Small-Cap Catalyst Pharma Is Among Market's Best Price Performers
Receive News & Ratings for Deep Medicine Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deep Medicine Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.